Although pulmonary hypertension as a result of interstitial lung disease is linked to significant morbidity and mortality, there is no consensus regarding screening or management of the disease.
An increase in circulating serum mitochondrial DNA is associated with worse survival in patients with newly diagnosed idiopathic pulmonary fibrosis.
Positive topline data from the phase 2b study of INOpulse® delivery system announced for the treatment of pulmonary hypertension associated with pulmonary fibrosis.
Use of thrombomodulin alfa for the treatment of acute exacerbation of idiopathic pulmonary fibrosis is not recommended, according to phase 3 clinical trial results.
Patients with idiopathic pulmonary fibrosis are faced with a heavy economic burden, with mean annual costs for admission and inpatient care totaling more than $10,000 per patient.
Altered expression of 14 genes in adults was associated with idiopathic pulmonary fibrosis susceptibility.
Persistent or chronic, but not acute, viral infections significantly increase the risk of developing idiopathic pulmonary fibrosis.
Use of home oxygen is associated with reduced physical function in patients with either COPD or idiopathic pulmonary fibrosis.
Patients with sarcoidosis on the lung transplant waiting list had a higher mortality rate than patients with chronic obstructive pulmonary disease or idiopathic pulmonary fibrosis.
Plasma biomarkers of progressive idiopathic pulmonary fibrosis may be markers of progressive pulmonary fibrosis regardless of the type of interstitial lung disease.
